Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK Plc receives Japan approval for Blenrep combinations in multiple myeloma

GSK's Blenrep combinations gain approval in Japan for relapsed multiple myeloma, offering promising treatment options backed by successful clinical trial results...

May 19, 2025

Nuformix to present NXP002 data at ATS 2025

Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...

May 19, 2025

One Health Group unlocks new potential in spinal treatment

Experience relief from back pain with One Health Group, a leader in spinal care. Their expert team offers personalised, advanced treatments for improved mobility and quality of life...

May 16, 2025

Aptamer secures repeat contracts and new licensing deals

Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases...

May 15, 2025

GSK Plc to acquire Efimosfermin for $2 billion, targeting steatotic liver disease

GSK is set to acquire Boston Pharmaceuticals' promising liver disease treatment, efimosfermin alfa, enhancing its hepatology pipeline and addressing critical patient needs...

May 14, 2025

hVIVO proves it can deliver big on high-volume vaccine trials

hVIVO has showcased its excellence in clinical research by successfully executing a large-scale flu vaccine trial, demonstrating agility and operational expertise under tight deadlines...

May 13, 2025

POLB 001 targets deadly cytokine storms in cancer therapy

Cytokine Release Syndrome (CRS) complicates cancer immunotherapy, but Poolbeg Pharma’s POLB 001 offers a groundbreaking oral solution to enhance patient outcomes...

May 12, 2025

hVIVO publishes 2024 report and announces Board changes

hVIVO plc announces the release of its 2024 Annual Report and upcoming AGM, along with notable board changes, including the departure of key directors...

May 12, 2025

Unlocking the potential of clinical trials at FluCamp

Investing in clinical research with FluCamp means supporting innovative healthcare solutions while ensuring participant welfare through unique trial methodologies...

May 9, 2025

AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC

AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...

May 9, 2025

One Health Group backs Scunthorpe healthcare expansion

Scunthorpe's healthcare evolution is attracting investors as One Health Group plans a new surgical hub, enhancing patient care and driving financial growth...

May 8, 2025

Severe influenza demands a smarter approach

Severe influenza is a critical health challenge that demands innovative solutions. Learn how advanced technologies are transforming care for high-risk populations...

May 7, 2025

Targeting inflammation with precision in viral challenge trials

Discover hVIVO's groundbreaking studies on immunomodulators presented at ESCMID 2025, revealing insights into viral infections and host immune responses...

May 7, 2025

Syncona’s Beacon reports positive 6-month data from XLRP trial

Syncona Ltd's portfolio company, Beacon Therapeutics, reveals promising Phase II DAWN trial results for laru-zova, targeting X-linked retinitis pigmentosa (XLRP)...

May 7, 2025

Nuformix advancing IPF treatment with NXP002 orphan drug designation (LON:NFX)

Nuformix Plc's Dr. Dan Gooding discusses the EMA's positive orphan drug designation for NXP002, highlighting its significance in treating idiopathic pulmonary fibrosis...

May 6, 2025

AstraZeneca Plc Calquence combo approved in EU for first-line MCL

AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...

May 6, 2025

Aptamer adapts Alzheimer’s test to ELISA and signs royalty deal

Aptamer Group announces a breakthrough in Alzheimer's diagnostics with a new ELISA test utilising saliva samples, enhancing accessibility and rapid detection...

May 6, 2025

AstraZeneca Plc Breztri succeeds in Phase III asthma trials

AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...

May 2, 2025

Nuformix advances NXP002 as EMA backs Orphan Drug status

Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights...

May 2, 2025

Why asthma shouldn’t stop you investing in the power of exercise

Asthma affects millions, but with the right management and support from FluCamp, individuals can embrace exercise for better health. Discover more today!..

May 1, 2025

News and Interview Alerts

Company Presentations

Tirupati Graphite overview – Critical materials for green economy

Dekel Agri-Vision Investor Presentation 2022

Goodbody Health investor presentation – Diagnostic services, health and wellness products

CyanConnode hugely strengthened financials, contracted partners and future pipeline (Interview)

Q&As

One Health Group outlines strong H1 growth and NHS-focused expansion plans

1 October 2025

Hardman & Co

NB Private Equity Partners 2025 CMD: good returns from low-risk PE model

10 December 2025

Real Estate Credit Investments (RECI): Investor Day: opportunities aplenty

2 December 2025

Volta Finance: Liquid access to outperforming private credit

6 October 2025

Real Estate Credit Investments: What RECI brings to investors

15 September 2025

Chesnara Plc: Showing good operational progress

8 September 2025

Green News

Drax expands FlexGen platform with Flexitricity acquisition

21 January 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

BrokerTalk

Ampeak Energy, updated forecasts and a growing BESS pipeline, Zeus Capital

29 August 2025

Ilika hits Stereax production milestone with Cirtec, Cavendish

20 August 2025

Kepler highlights strong gains for JPMorgan European Discovery

13 August 2025

EDX Medical Group: Pioneering the Future of Digital Diagnostics – Oberon Capital

12 August 2025

Funds

CQS Natural Resources Growth & Income plc

CQS Natural Resources Growth and Income double-digit NAV and share price gains in Dec 2025

22 January 2026

RECI reports strong longer-term NAV performance to December 2025

20 January 2026

Oil’s slide creates opening as market sentiment shifts | Ruffer Investment Company

16 January 2026

How FCSS is harnessing China’s innovation – Kepler Research

15 January 2026

View all Funds, Market Insights and news >>

FTSE 100 News

UK Broker Ratings

Spire Healthcare Group PLC (SPI.L) Stock Analysis: Navigating a 48.47% Potential Upside Amid Market Challenges

22 January 2026

Dr. Martens PLC (DOCS.L) Stock Analysis: Exploring the 35% Potential Upside in a Challenging Market

22 January 2026

Syncona Limited (SYNC.L) Stock Analysis: Analyst Consensus Points to Stunning 104% Upside

22 January 2026

Senior plc (SNR.L) Stock Analysis: Navigating the Aerospace & Defense Landscape with a 2.7% Upside

22 January 2026

Softcat PLC (SCT.L) Stock Analysis: A Strong ROI with 28% Potential Upside for Tech Investors

22 January 2026

November 24, 2025

GSK Plc receives Japan approval for Blenrep combinations in multiple myeloma

GSK's Blenrep combinations gain approval in Japan for relapsed multiple myeloma, offering promising treatment options backed by successful clinical trial results...

May 19, 2025

Nuformix to present NXP002 data at ATS 2025

Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...

May 19, 2025

One Health Group unlocks new potential in spinal treatment

Experience relief from back pain with One Health Group, a leader in spinal care. Their expert team offers personalised, advanced treatments for improved mobility and quality of life...

May 16, 2025

Aptamer secures repeat contracts and new licensing deals

Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases...

May 15, 2025

GSK Plc to acquire Efimosfermin for $2 billion, targeting steatotic liver disease

GSK is set to acquire Boston Pharmaceuticals' promising liver disease treatment, efimosfermin alfa, enhancing its hepatology pipeline and addressing critical patient needs...

May 14, 2025

hVIVO proves it can deliver big on high-volume vaccine trials

hVIVO has showcased its excellence in clinical research by successfully executing a large-scale flu vaccine trial, demonstrating agility and operational expertise under tight deadlines...

May 13, 2025

POLB 001 targets deadly cytokine storms in cancer therapy

Cytokine Release Syndrome (CRS) complicates cancer immunotherapy, but Poolbeg Pharma’s POLB 001 offers a groundbreaking oral solution to enhance patient outcomes...

May 12, 2025

hVIVO publishes 2024 report and announces Board changes

hVIVO plc announces the release of its 2024 Annual Report and upcoming AGM, along with notable board changes, including the departure of key directors...

May 12, 2025

Unlocking the potential of clinical trials at FluCamp

Investing in clinical research with FluCamp means supporting innovative healthcare solutions while ensuring participant welfare through unique trial methodologies...

May 9, 2025

AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC

AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...

May 9, 2025

One Health Group backs Scunthorpe healthcare expansion

Scunthorpe's healthcare evolution is attracting investors as One Health Group plans a new surgical hub, enhancing patient care and driving financial growth...

May 8, 2025

Severe influenza demands a smarter approach

Severe influenza is a critical health challenge that demands innovative solutions. Learn how advanced technologies are transforming care for high-risk populations...

May 7, 2025

Targeting inflammation with precision in viral challenge trials

Discover hVIVO's groundbreaking studies on immunomodulators presented at ESCMID 2025, revealing insights into viral infections and host immune responses...

May 7, 2025

Syncona’s Beacon reports positive 6-month data from XLRP trial

Syncona Ltd's portfolio company, Beacon Therapeutics, reveals promising Phase II DAWN trial results for laru-zova, targeting X-linked retinitis pigmentosa (XLRP)...

May 7, 2025

Nuformix advancing IPF treatment with NXP002 orphan drug designation (LON:NFX)

Nuformix Plc's Dr. Dan Gooding discusses the EMA's positive orphan drug designation for NXP002, highlighting its significance in treating idiopathic pulmonary fibrosis...

May 6, 2025

AstraZeneca Plc Calquence combo approved in EU for first-line MCL

AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...

May 6, 2025

Aptamer adapts Alzheimer’s test to ELISA and signs royalty deal

Aptamer Group announces a breakthrough in Alzheimer's diagnostics with a new ELISA test utilising saliva samples, enhancing accessibility and rapid detection...

May 6, 2025

AstraZeneca Plc Breztri succeeds in Phase III asthma trials

AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...

May 2, 2025

Nuformix advances NXP002 as EMA backs Orphan Drug status

Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights...

May 2, 2025

Why asthma shouldn’t stop you investing in the power of exercise

Asthma affects millions, but with the right management and support from FluCamp, individuals can embrace exercise for better health. Discover more today!..

May 1, 2025